GlobeNewswire: Wave Life Sciences USA, Inc. Contains the last 10 of 144 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T07:22:16ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/27/2853165/0/en/Wave-Life-Sciences-to-Present-at-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=42970Wave Life Sciences to Present at Upcoming Investor Conferences2024-03-27T12:30:00Z<![CDATA[CAMBRIDGE, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences in April.]]>https://www.globenewswire.com/news-release/2024/03/06/2841296/0/en/Wave-Life-Sciences-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=42970Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update2024-03-06T12:30:00Z<![CDATA[INHBE lead clinical candidate selected; potential best-in-class treatment for obesity with potent and durable silencing, weight loss with no loss of muscle mass, reduction of visceral fat, and every-six-month or annual subcutaneous dosing; clinical trial initiation expected 1Q 2025]]>https://www.globenewswire.com/news-release/2024/02/28/2836961/0/en/Wave-Life-Sciences-Fourth-Quarter-and-Full-Year-2023-Financial-Results-Scheduled-for-March-6-2024.html?f=22&fvtc=4&fvtv=42970Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 20242024-02-28T13:30:00Z<![CDATA[CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, March 6, 2024, to review the company’s fourth quarter and full year 2023 financial results and provide business updates.]]>https://www.globenewswire.com/news-release/2024/02/27/2836039/0/en/Wave-Life-Sciences-Announces-Upcoming-Presentations-at-MDA-Conference-that-Highlight-Best-in-Class-Potential-for-WVE-N531-in-Duchenne-Muscular-Dystrophy.html?f=22&fvtc=4&fvtv=42970Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy2024-02-27T13:30:00Z<![CDATA[Presentations include data for WVE-N531 that provide first clinical evidence of a potential therapeutic for DMD accessing satellite cells, which are important for potential muscle regeneration]]>https://www.globenewswire.com/news-release/2024/01/08/2805412/0/en/Wave-Life-Sciences-Highlights-Recent-Achievements-and-Upcoming-2024-Milestones.html?f=22&fvtc=4&fvtv=42970Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones2024-01-08T13:00:00Z<![CDATA[Multiple data catalysts across all clinical programs expected throughout 2024, including data for WVE-006 in AATD which would provide first-ever RNA editing proof-of-mechanism in humans]]>https://www.globenewswire.com/news-release/2024/01/03/2803312/0/en/Wave-Life-Sciences-to-Present-at-42nd-Annual-J-P-Morgan-Healthcare-Conference.html?f=22&fvtc=4&fvtv=42970Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference2024-01-03T13:30:00Z<![CDATA[CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024, at 3:00 p.m. PT / 6:00 p.m. ET.]]>https://www.globenewswire.com/news-release/2023/12/15/2797042/0/en/Wave-Life-Sciences-Announces-Initiation-of-Dosing-in-Phase-2-FORWARD-53-Trial-of-WVE-N531-in-Duchenne-Muscular-Dystrophy.html?f=22&fvtc=4&fvtv=42970Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy2023-12-15T13:30:00Z<![CDATA[FORWARD-53 is fully enrolled with potentially registrational dystrophin expression data expected in 2024]]>https://www.globenewswire.com/news-release/2023/12/07/2792392/0/en/Wave-Life-Sciences-Prices-100-Million-Public-Offering-of-Ordinary-Shares.html?f=22&fvtc=4&fvtv=42970Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares2023-12-07T12:00:00Z<![CDATA[CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today the pricing of its previously announced underwritten public offering of 20,000,000 of its ordinary shares at a price to the public of $5.00 per ordinary share. Gross proceeds to Wave Life Sciences from the offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and offering expenses. All of the ordinary shares in the offering are being sold by Wave Life Sciences. In addition, Wave Life Sciences has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 of its ordinary shares on the same terms and conditions. The offering is expected to close on or about December 11, 2023, subject to customary closing conditions.]]>https://www.globenewswire.com/news-release/2023/12/06/2792104/0/en/Wave-Life-Sciences-Announces-Proposed-Public-Offering-of-Ordinary-Shares-and-Pre-Funded-Warrants.html?f=22&fvtc=4&fvtv=42970Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants2023-12-06T21:10:17Z<![CDATA[CAMBRIDGE, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that it has commenced an underwritten public offering of $100 million in aggregate of its ordinary shares, and, to certain investors that so choose in lieu of ordinary shares, pre-funded warrants to purchase ordinary shares. In connection with the offering, Wave intends to grant the underwriters a 30-day option to purchase ordinary shares in an amount up to an additional 15% of the total amount of ordinary shares and pre-funded warrants sold in the public offering on the same terms and conditions. All of the securities in the offering will be sold by Wave Life Sciences.]]>https://www.globenewswire.com/news-release/2023/12/06/2792102/0/en/Wave-Life-Sciences-Announces-Initiation-of-Dosing-in-RestorAATion-Clinical-Program-Evaluating-First-Ever-RNA-Editing-Candidate-WVE-006-for-Alpha-1-Antitrypsin-Deficiency.html?f=22&fvtc=4&fvtv=42970Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency2023-12-06T21:08:49Z<![CDATA[WVE-006 is uniquely designed to correct the disease-causing RNA mutation in AATD, thereby restoring circulation of wild-type M-AAT protein and reducing Z-AAT protein levels to address both lung and liver manifestations of the disease]]>